Atrial fibrillation in the intensive care setting

Journal of the Intensive Care Society

Volumn 14, Issue 2, 2013, Pages 141-149

  Malik, A ^a   Candilio, L ^a   Hausenloy, Derek J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Atrial fibrillation; Diagnosis and treatment; Intensive care; Review

Indexed keywords

AMIODARONE; APIXABAN; ATENOLOL; BISOPROLOL; CARVEDILOL; DABIGATRAN; DIGITOXIN; DIGOXIN; DILTIAZEM; DOFETILIDE; DRONEDARONE; EDOXABAN; ESMOLOL; FLECAINIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUTILIDE; MAGNESIUM; METOPROLOL; PLACEBO; PROPAFENONE; PROPRANOLOL; SOTALOL; VERAPAMIL;

CARDIOVERSION; CLINICAL FEATURE; DISEASE PREDISPOSITION; ELECTROCARDIOGRAM; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HUMAN; HYPOMAGNESEMIA; INTENSIVE CARE; INTENSIVE CARE UNIT; LIVER TOXICITY; LUNG FIBROSIS; META ANALYSIS (TOPIC); NAUSEA; PNEUMONIA; POLYMORPHIC VENTRICULAR TACHYCARDIA; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SKIN DISEASE; THYROID DISEASE; TORSADE DES POINTES; VOMITING;

EID: 84878455071     PISSN: 17511437     EISSN: None     Source Type: Journal    
DOI: 10.1177/175114371301400212     Document Type: Review

References (60)

1. Bellet S. Clinical disorders of the heart beat. Clinics 1946;5:190-234.
2. Camm AJ, Kirchhof P, Lip GY et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010;12: 1360-420.
3. Lloyd-Jones DM, Wang TJ, Leip EP et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004;110: 1042-46.
4. Stewart S, Hart CL, Hole DJ, McMurray JJ. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart 2001;86:516-21.
5. Go AS, Hylek EM, Phillips KA et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-75.
6. Seguin P, Signouret T, Laviolle B et al. Incidence and risk factors of atrial fibrillation in a surgical intensive care unit. Crit Care Med 2004;32: 722-26.
7. Meierhenrich R, Steinhilber E, Eggermann C et al. Incidence and prognostic impact of new-onset atrial fibrillation in patients with septic shock: a prospective observational study. Crit Care 2010;14:R108.
8. Kanji S, Williamson DR, Yaghchi BM et al. Epidemiology and management of atrial fibrillation in medical and noncardiac surgical adult intensive care unit patients. J Crit Care 2012;27:326.e1-8.
9. Crystal E, Garfinkle MS, Connolly SS et al. Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery. Cochrane Database Syst Rev 2004: CD003611.
10. Andrews TC, Reimold SC, Berlin JA, Antman EM. Prevention of supraventricular arrhythmias after coronary artery bypass surgery. A metaanalysis of randomized control trials. Circulation 1991;84(5 Suppl): III236-44.
11. Mathew JP, Fontes ML, Tudor IC et al. A multicenter risk index for atrial fibrillation after cardiac surgery. JAMA 2004;291:1720-29.
12. Almassi GH, Schowalter T, Nicolosi AC et al. Atrial fibrillation after cardiac surgery: a major morbid event? Ann Surg 1997; 226: 501-11; discussion 11-13.
13. Creswell LL, Schuessler RB, Rosenbloom M, Cox JL. Hazards of postoperative atrial arrhythmias. Ann Thor Surg 1993;56:539-49.
14. Levy S, Maarek M, Coumel P, Guize L et al. Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. The College of French Cardiologists. Circulation 1999;99:3028-35.
15. Potpara TS, Lip GY. Lone atrial fibrillation: what is known and what is to come. Int J Clin Prac 2011;65:446-57.
16. Cavaliere F, Volpe C, Soave M. Atrial fibrillation in intensive care units. Curr Anaesth Crit Care 2006;17:367-74.
17. Brathwaite D, Weissman C. The new onset of atrial arrhythmias following major noncardiothoracic surgery is associated with increased mortality. Chest 1998;114:462-68.
18. Kuhlkamp V, Haasis R, Seipel L. Atrial vulnerability and electrophysiology determined in patients with and without paroxysmal atrial fibrillation. Pacing Clin Electrophysiol 1992;15:71-80.
19. Michelucci A, Padeletti L, Fradella GA et al. Aging and atrial electrophysiologic properties in man. Int J Cardiol 1984;5:75-81.
20. Chung MK, Martin DO, Sprecher D et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001;104:2886-91.
21. Simpson RJ, Foster JR, Mulrow JP, Gettes LS. The electrophysiological substrate of atrial fibrillation. Pacing Clin Electrophysiol 1983;6(5 Pt 2):1166-70.
22. Coumel P. Paroxysmal atrial fibrillation: a disorder of autonomic tone? Eur Heart J 1994;15 Suppl A:9-16.
23. Chun JG, Brodsky MA, Allen BJ. Modern concepts of atrial fibrillation. Herz 1993;18:67-75.
24. Lammers WJ, Allessie MA. Pathophysiology of atrial fibrillation: current aspects. Herz 1993;18:1-8.
25. Knotzer H, Mayr A, Ulmer H et al. Tachyarrhythmias in a surgical intensive care unit: a case-controlled epidemiologic study. Intensive Care Med 2000;26:908-14.
26. Iseri LT, Allen BJ, Ginkel ML, Brodsky MA. Ionic biology and ionic medicine in cardiac arrhythmias with particular reference to magnesium. Am Heart J 1992;123:1404-09.
27. Polderman KH, Girbes AJ. Central venous catheter use. Part 1: mechanical complications. Intensive Care Med 2002;28:1-17.
28. Frost L, Christiansen EH, Molgaard H et al. Premature atrial beat eliciting atrial fibrillation after coronary artery bypass grafting. J Electrocardiol 1995;28:297-305.
29. Kaireviciute D, Aidietis A, Lip GY. Atrial fibrillation following cardiac surgery: clinical features and preventative strategies. Eur Heart J 2009;30:410-25.
30. Channer KS, Jones JV. Atrial systole: its role in normal and diseased hearts. Clin Sci (Lond) 1988;75:1-4.
31. Klabunde RE. Cardiovascular Physiology Concepts. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins/Wolters Kluwer; 2012. xi, p. 243.
32. Amar D, Roistacher N, Burt M et al. Clinical and echocardiographic correlates of symptomatic tachydysrhythmias after noncardiac thoracic surgery. Chest 1995;108:349-54.
33. Hobbs FD, Fitzmaurice DA, Mant J et al. A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study. Health Technol Assess. 2005;9(40):iii-iv, ix-x, 1-74.
34. Kirchhof P, Auricchio A, Bax J et al. Outcome parameters for trials in atrial fibrillation: executive summary. Eur Heart J 2007;28:2803-17.
35. Topol EJ, Califf RM. Textbook of Cardiovascular Medicine. Philadelphia: Lippincott-Raven; 1998. xxvii, p. 2732.
36. Levy S, Breithardt G, Campbell RW et al. Atrial fibrillation: current knowledge and recommendations for management. Working Group on Arrhythmias of the European Society of Cardiology. Eur Heart J 1998;19:1294-320.
37. Seguin P, Launey Y. Atrial fibrillation is not just an artefact in the ICU. Crit Care 2010;14:182.
38. Christian SA, Schorr C, Ferchau L et al. Clinical characteristics and outcomes of septic patients with new-onset atrial fibrillation. J Crit Care 2008;23:532-36.
39. Walkey AJ, Wiener RS, Ghobrial JM et al. Incident stroke and mortality associated with new-onset atrial fibrillation in patients hospitalized with severe sepsis. JAMA 2011;306:2248-54.
40. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Int Med 1987;147:1561-64.
41. Thrall G, Lane D, Carroll D, Lip GY. Quality of life in patients with atrial fibrillation: a systematic review. Am J Med 2006;119:448 e1-19.
42. Levy S, Camm AJ, Saksena S et al. International consensus on nomenclature and classification of atrial fibrillation; a collaborative project of the Working Group on Arrhythmias and the Working Group on Cardiac Pacing of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Europace 2003;5: 119-22.
43. Kinnear JHD, Stone A, Armstrong M. New-onset atrial fibrillation in the intensive care unit: a survey of current practice in the United Kingdom. Eur J Anaesthesiol 2007;24:159.
44. Sleeswijk ME, Van Noord T, Tulleken JE et al. Clinical review: treatment of new-onset atrial fibrillation in medical intensive care patients--a clinical framework. Crit Care 2007;11:233.
45. Dunning J, Treasure T, Versteegh M, Nashef SA. Guidelines on the prevention and management of de novo atrial fibrillation after cardiac and thoracic surgery. Eur J Cardiothorac Surg 2006;30:852-72.
46. Lown B, Perlroth MG, Kaidbey S et al. "Cardioversion" of atrial fibrillation. A report on the treatment of 65 episodes in 50 patients. N Engl J Med 1963;269:325-31.
47. Wyse DG, Waldo AL, DiMarco JP et al A comparison of rate control and rhythm control in patients with atrial fibrillation. New Engl J Med 2002;347:1825-33.
48. Saksena S, Slee A, Waldo AL et al. Cardiovascular outcomes in the AFFIRM Trial (Atrial Fibrillation Follow-Up Investigation of Rhythm Management). An assessment of individual antiarrhythmic drug therapies compared with rate control with propensity score-matched analyses. J Am Coll Cardiol 2011;58:1975-85.
49. Vittorio TJ, Zolty R, Kasper ME et al. Differential effects of carvedilol and metoprolol succinate on plasma norepinephrine release and peak exercise heart rate in subjects with chronic heart failure. J Cardiovasc Pharm Ther 2008;13:51-57.
50. Bagshaw SM, Galbraith PD, Mitchell LB et al. Prophylactic amiodarone for prevention of atrial fibrillation after cardiac surgery: a meta-analysis. Ann Thor Surg 2006;82:1927-37.
51. Patel AA, White CM, Gillespie EL et al. Safety of amiodarone in the prevention of postoperative atrial fibrillation: a meta-analysis. Am J Health Syst Pharm 2006;63:829-37.
52. Miller S, Crystal E, Garfinkle M et al. Effects of magnesium on atrial fibrillation after cardiac surgery: a meta-analysis. Heart 2005;91:618-23.
53. Savelieva I, Camm J. Statins and polyunsaturated fatty acids for treatment of atrial fibrillation. Nat Clin Prac Cardiovasc Med 2008;5:30-41.
54. Savelieva I, Kourliouros A, Camm J. Primary and secondary prevention of atrial fibrillation with statins and polyunsaturated fatty acids: review of evidence and clinical relevance. Naunyn-Schmiedeberg's Arch Pharm 2010;381:1-13.
55. Ho KM, Tan JA. Benefits and risks of corticosteroid prophylaxis in adult cardiac surgery: a dose-response meta-analysis. Circulation 2009;119: 1853-66.
56. Daoud EG. Management of atrial fibrillation in the post-cardiac surgery setting. Cardiol Clin 2004;22:159-66.
57. Mittal MK, Rabinstein AA. Anticoagulation-related intracranial hemorrhages. Curr Atheroscler Rep 2012;14:351-59.
58. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.
59. Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91.
60. Blomstrom-Lundqvist C, Scheinman MM et al. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary. a report of the American College of Cardiology/American Heart Association Task force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias) developed in collaboration with NASPE-Heart Rhythm Society. J Am Coll of Cardiol 2003;42:1493-531.